KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Biomarin Pharmaceutical (BMRN) Net Margin (2017 - 2025)

Historic Net Margin for Biomarin Pharmaceutical (BMRN) over the last 16 years, with Q3 2025 value amounting to 3.96%.

  • Biomarin Pharmaceutical's Net Margin fell 181900.0% to 3.96% in Q3 2025 from the same period last year, while for Sep 2025 it was 16.82%, marking a year-over-year increase of 51100.0%. This contributed to the annual value of 14.96% for FY2024, which is 80300.0% up from last year.
  • Biomarin Pharmaceutical's Net Margin amounted to 3.96% in Q3 2025, which was down 181900.0% from 29.14% recorded in Q2 2025.
  • Over the past 5 years, Biomarin Pharmaceutical's Net Margin peaked at 29.14% during Q2 2025, and registered a low of 12.87% during Q4 2021.
  • Its 5-year average for Net Margin is 7.85%, with a median of 6.95% in 2023.
  • As far as peak fluctuations go, Biomarin Pharmaceutical's Net Margin crashed by -1735300bps in 2021, and later soared by 196800bps in 2022.
  • Quarter analysis of 5 years shows Biomarin Pharmaceutical's Net Margin stood at 12.87% in 2021, then soared by 100bps to 0.05% in 2022, then skyrocketed by 6907bps to 3.15% in 2023, then skyrocketed by 430bps to 16.72% in 2024, then tumbled by -124bps to 3.96% in 2025.
  • Its Net Margin was 3.96% in Q3 2025, compared to 29.14% in Q2 2025 and 24.92% in Q1 2025.